Sara Lodi1, Matthew Freiberg2, Natalia Gnatienko3, Elena Blokhina4, Tatiana Yaroslavtseva4, Evgeny Krupitsky4,5, Eleanor Murray6, Jeffrey H Samet7,8, Debbie M Cheng9. 1. Department of Biostatistics, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02118, USA. slodi@bu.edu. 2. Vanderbilt Center for Clinical Cardiovascular Trials Evaluation (V-C3REATE), Cardiovascular Division, Vanderbilt University Medical Center, Nashville, TN, USA. 3. Department of Medicine, Section of General Internal Medicine, Boston Medical Center, Clinical Addiction Research and Education (CARE) Unit, Boston, MA, USA. 4. First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation. 5. Department of Addictions, V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, St. Petersburg, Russian Federation. 6. Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA. 7. Department of Medicine, Section of General Internal Medicine, Boston Medical Center, Clinical Addiction Research and Education (CARE) Unit, Boston University School of Medicine, Boston, MA, USA. 8. Department of Community Health Sciences, Boston University School of Public Health, Boston, MA, USA. 9. Department of Biostatistics, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, 02118, USA.
Abstract
BACKGROUND: The Zinc for INflammation and Chronic disease in HIV (ZINC) trial randomized person who live with HIV (PLWH) who engage in heavy drinking to either daily zinc supplementation or placebo. The primary outcome was change in the Veterans Aging Cohort Study (VACS) index, a predictor of mortality, between baseline and 18 months. Because adherence and follow-up were suboptimal, the intention-to-treat analysis, which was not statistically significant, may have underestimated the effect of the zinc supplementation. OBJECTIVE: We estimated the per-protocol effect of zinc versus placebo in the ZINC trial (i.e., the effect that would have been observed if all participants had had high adherence and none was lost to follow-up). METHODS: Adherence was measured as the self-reported percentage of pills taken in the previous 6 weeks and assessed at all post-baseline visits. We used inverse probability weighting to estimate and compare the change in the VACS index at 18 months in the zinc and placebo groups, had all the trial participants had high adherence (i.e., cumulative adherence ≥80% at 18 months). To examine trends by level of adherence, we rerun the analyses using thresholds for high adherence of 70% and 90% of average self-reported pill coverage. RESULTS: The estimated (95% confidence interval) change in the VACS index was - 2.16 (- 8.07, 3.59) and 5.84 (0.73, 11.80) under high adherence and no loss to follow-up in the zinc and placebo groups, respectively. The per-protocol effect estimate of the mean difference in the change between the zinc and placebo groups was - 8.01 (- 16.42, 0.01), somewhat larger than the intention-to-treat effect difference in change (- 4.68 (- 9.62, 0.25)), but it was still not statistically significant. The mean difference in the change between individuals in the zinc and placebo groups was - 4.07 (- 11.5, 2.75) and -12.34 (- 20.14, -4.14) for high adherence defined as 70% and 90% of pill coverage, respectively. CONCLUSIONS: Overall, high adherence to zinc was associated with a lower VACS score, but confidence intervals were wide and crossed 0. Further studies with a larger sample size are needed to quantify the benefits of zinc supplementation in this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT01934803 . Registered on August 30, 2013.
BACKGROUND: The Zinc for INflammation and Chronic disease in HIV (ZINC) trial randomized person who live with HIV (PLWH) who engage in heavy drinking to either daily zinc supplementation or placebo. The primary outcome was change in the Veterans Aging Cohort Study (VACS) index, a predictor of mortality, between baseline and 18 months. Because adherence and follow-up were suboptimal, the intention-to-treat analysis, which was not statistically significant, may have underestimated the effect of the zinc supplementation. OBJECTIVE: We estimated the per-protocol effect of zinc versus placebo in the ZINC trial (i.e., the effect that would have been observed if all participants had had high adherence and none was lost to follow-up). METHODS: Adherence was measured as the self-reported percentage of pills taken in the previous 6 weeks and assessed at all post-baseline visits. We used inverse probability weighting to estimate and compare the change in the VACS index at 18 months in the zinc and placebo groups, had all the trial participants had high adherence (i.e., cumulative adherence ≥80% at 18 months). To examine trends by level of adherence, we rerun the analyses using thresholds for high adherence of 70% and 90% of average self-reported pill coverage. RESULTS: The estimated (95% confidence interval) change in the VACS index was - 2.16 (- 8.07, 3.59) and 5.84 (0.73, 11.80) under high adherence and no loss to follow-up in the zinc and placebo groups, respectively. The per-protocol effect estimate of the mean difference in the change between the zinc and placebo groups was - 8.01 (- 16.42, 0.01), somewhat larger than the intention-to-treat effect difference in change (- 4.68 (- 9.62, 0.25)), but it was still not statistically significant. The mean difference in the change between individuals in the zinc and placebo groups was - 4.07 (- 11.5, 2.75) and -12.34 (- 20.14, -4.14) for high adherence defined as 70% and 90% of pill coverage, respectively. CONCLUSIONS: Overall, high adherence to zinc was associated with a lower VACS score, but confidence intervals were wide and crossed 0. Further studies with a larger sample size are needed to quantify the benefits of zinc supplementation in this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT01934803 . Registered on August 30, 2013.
Entities:
Keywords:
Alcohol abuse; HIV; Inverse probability weighting; Per-protocol; Zinc
Authors: Bin Bao; Ananda S Prasad; Frances W J Beck; James T Fitzgerald; Diane Snell; Ginny W Bao; Tapinder Singh; Lavoisier J Cardozo Journal: Am J Clin Nutr Date: 2010-04-28 Impact factor: 7.045
Authors: Pamela M Murnane; Connie Celum; Nelly Mugo; James D Campbell; Deborah Donnell; Elizabeth Bukusi; Andrew Mujugira; Jordan Tappero; Erin M Kahle; Katherine K Thomas; Jared M Baeten Journal: AIDS Date: 2013-08-24 Impact factor: 4.177
Authors: Natalia Gnatienko; Matthew S Freiberg; Elena Blokhina; Tatiana Yaroslavtseva; Carly Bridden; Debbie M Cheng; Christine E Chaisson; Dmitry Lioznov; Sally Bendiks; Glory Koerbel; Sharon M Coleman; Evgeny Krupitsky; Jeffrey H Samet Journal: HIV Clin Trials Date: 2018-04-17
Authors: Sara Lodi; Shweta Sharma; Jens D Lundgren; Andrew N Phillips; Stephen R Cole; Roger Logan; Brian K Agan; Abdel Babiker; Hartwig Klinker; Haitao Chu; Matthew Law; James D Neaton; Miguel A Hernán Journal: AIDS Date: 2016-11-13 Impact factor: 4.177
Authors: Amy C Justice; Sharada P Modur; Janet P Tate; Keri N Althoff; Lisa P Jacobson; Kelly A Gebo; Mari M Kitahata; Michael A Horberg; John T Brooks; Kate Buchacz; Sean B Rourke; Anita Rachlis; Sonia Napravnik; Joseph Eron; James H Willig; Richard Moore; Gregory D Kirk; Ronald Bosch; Benigno Rodriguez; Robert S Hogg; Jennifer Thorne; James J Goedert; Marina Klein; John Gill; Steven Deeks; Timothy R Sterling; Kathryn Anastos; Stephen J Gange Journal: J Acquir Immune Defic Syndr Date: 2013-02-01 Impact factor: 3.731
Authors: Sara Lodi; Andrew Phillips; Jens Lundgren; Roger Logan; Shweta Sharma; Stephen R Cole; Abdel Babiker; Matthew Law; Haitao Chu; Dana Byrne; Andrzej Horban; Jonathan A C Sterne; Kholoud Porter; Caroline Sabin; Dominique Costagliola; Sophie Abgrall; John Gill; Giota Touloumi; Antonio G Pacheco; Ard van Sighem; Peter Reiss; Heiner C Bucher; Alexandra Montoliu Giménez; Inmaculada Jarrin; Linda Wittkop; Laurence Meyer; Santiago Perez-Hoyos; Amy Justice; James D Neaton; Miguel A Hernán Journal: Am J Epidemiol Date: 2019-08-01 Impact factor: 5.363
Authors: Matthew S Freiberg; Debbie M Cheng; Natalia Gnatienko; Elena Blokhina; Sharon M Coleman; Margaret F Doyle; Tatiana Yaroslavtseva; Carly Bridden; Kaku So-Armah; Russell Tracy; Kendall Bryant; Dmitry Lioznov; Evgeny Krupitsky; Jeffrey H Samet Journal: JAMA Netw Open Date: 2020-05-01